このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Biodesix 過去の業績

過去基準チェック /06

Biodesixの収益は年間平均-18.8%の割合で減少していますが、 Healthcare業界の収益は年間増加しています。収益は年間5.6% 16.1%割合で減少しています。

主要情報

-18.8%

収益成長率

99.5%

EPS成長率

Healthcare 業界の成長	8.5%
収益成長率	-16.1%
株主資本利益率	n/a
ネット・マージン	-85.8%
前回の決算情報	31 Mar 2024

Recent updates

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

Jun 12

With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Mar 03

Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

Jan 04

Need To Know: Analysts Just Made A Substantial Cut To Their Biodesix, Inc. (NASDAQ:BDSX) Estimates

Nov 25

Bearing In On Biodesix

Sep 13

Time To Worry? Analysts Are Downgrading Their Biodesix, Inc. (NASDAQ:BDSX) Outlook

Aug 16

Biodesix: Continued Concerns After The Boom-Bust Cycle

Jul 14

収支内訳

Biodesix の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGM:BDSX 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
31 Mar 24	55	-47	69	9
31 Dec 23	49	-52	67	10
30 Sep 23	44	-63	68	12
30 Jun 23	42	-66	67	13
31 Mar 23	41	-69	66	13
31 Dec 22	38	-65	61	13
30 Sep 22	36	-58	58	12
30 Jun 22	31	-56	57	13
31 Mar 22	32	-52	53	13
31 Dec 21	55	-43	51	13
30 Sep 21	74	-34	49	13
30 Jun 21	77	-32	43	12
31 Mar 21	69	-29	39	11
31 Dec 20	46	-31	35	11
30 Sep 20	27	-33	29	10
30 Jun 20	22	-34	30	10
31 Mar 20	23	-33	31	11
31 Dec 19	25	-31	31	10
31 Dec 18	20	-26	26	8

質の高い収益: BDSXは現在利益が出ていません。

利益率の向上: BDSXは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: BDSXは利益が出ておらず、過去 5 年間で損失は年間18.8%の割合で増加しています。

成長の加速: BDSXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: BDSXは利益が出ていないため、過去 1 年間の収益成長をHealthcare業界 ( 15.1% ) と比較することは困難です。

株主資本利益率

高いROE: BDSXの負債は資産を上回っているため、自己資本利益率を計算することは困難です。

Biodesix 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biodesix, Inc. to Report Q4, 2023 Results on Mar 01, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biodesix, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Recent updates

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

New major risk - Shareholder dilution

Biodesix, Inc. to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. to Report Q1, 2024 Results on May 08, 2024

Biodesix, Inc., Annual General Meeting, May 21, 2024

Biodesix, Inc. announced that it expects to receive $34.999422 million in funding

Biodesix, Inc. has completed a Follow-on Equity Offering in the amount of $20.000607 million.

With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2024

Biodesix, Inc. to Report Q4, 2023 Results on Mar 01, 2024

President notifies of intention to sell stock

Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

Biodesix, Inc. Enhances Access to Nodify Lung Testing with Launch of New Blood Draw Method

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2023

Biodesix, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New major risk - Share price stability

Biodesix, Inc. Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer

Independent Director recently bought US$217k worth of stock

Biodesix, Inc. Announces Presentation of New Nodify XL2(R) Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer

Consensus EPS estimates upgraded to US$0.68 loss

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. to Report Q2, 2023 Results on Aug 07, 2023

It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks

Biodesix, Inc. Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating That the Nodify XL2 Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

Biodesix, Inc. Receives Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services

Biodesix Completes Enrollment of Insight Study Assessing Clinical Utility of the Veristrat®? Blood-Based Host Immune Classifier

Biodesix, Inc. Announces Resignation of Ryan Siurek as Chief Accounting Officer, Effective July 3, 2023

Independent Director recently bought US$65k worth of stock

Biodesix, Inc. Announces New Clinical Utility Evidence for the Nodify XL2 Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Independent Director recently bought US$125k worth of stock

Biodesix Announces First Four Private Payer Coverage Policies for the Nodify Xl2® Test

Biodesix Announces First Four Private Payer Coverage Policies for the Nodify Xl2® Test

Biodesix, Inc. Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors and Audit Committee of the Board, Effective January 3, 2023

Independent Director recently bought US$148k worth of stock

Biodesix, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Price target decreased to US$5.00

Biodesix, Inc. Presents New Data from the Insight Study At the 2022 Society for Immunotherapy of Cancer 37Th Annual Meeting

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Provides Earnings Guidance for the Year 2022

Biodesix, Inc. to Report Q3, 2022 Results on Nov 03, 2022

A Second Look At Biodesix

Biodesix, Inc. Provides Revenue Guidance for the Third Quarter 2022

Biodesix expects Q3 revenue above the consensus

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2022

Biodesix GAAP EPS of -$0.40 beats by $0.07, revenue of $10.95M beats by $2.12M

Biodesix, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Biodesix, Inc.(NasdaqGM:BDSX) dropped from Russell 2000 Growth Index

Biodesix, Inc. Obtains Medicare Coverage for the Nodify CDT Lung Nodule Test

Biodesix: Bad Diagnosis

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2022

Price target decreased to US$9.00

High number of new directors

Consensus forecasts updated

Independent Director recently bought US$5.0m worth of stock

Biodesix, Inc., Annual General Meeting, May 24, 2022

Consensus revenue estimates increase by 10%

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Analysts' Revenue Estimates For Biodesix, Inc. (NASDAQ:BDSX) Are Surging Higher

Biodesix, Inc. Announces Impactful Clinical Data on the Primary Immune Response Test at IASLC 2022 Therapies of Lung Cancer Meeting

過去基準チェック /06